Indivior Pharmaceuticals (INDV) Deferred Taxes (2024 - 2026)

Indivior Pharmaceuticals' Deferred Taxes history runs 3 years deep, the most recent figure standing at $27.0 million for Q1 2026.

• In Q1 2026, Deferred Taxes rose 1450.0% year-over-year to $27.0 million; the TTM figure through Mar 2026 stood at -$17.0 million (down 950.0% YoY), while the FY2025 annual figure was -$46.0 million, down 757.14% from the prior year.
• Deferred Taxes was $27.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$38.0 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $37.0 million in Q4 2024 to a low of -$38.0 million in Q4 2025.
• Historically, Deferred Taxes has averaged -$1.3 million across 3 years, with a median of -$2.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Deferred Taxes tumbled 202.7% in 2025, then soared 1450.0% in 2026.
• A 3-year view of Deferred Taxes shows it stood at $37.0 million in 2024, then sank by 202.7% to -$38.0 million in 2025, then soared by 171.05% to $27.0 million in 2026.
• The last three Deferred Taxes figures came in at $27.0 million (Q1 2026), -$38.0 million (Q4 2025), and -$15.0 million (Q3 2025), per Business Quant data.